tirzepatide creatinine (Zepbound) showed improved kidney function in obese patients with both chronic kidney disease and #heartfailure with preserved ejection fraction, highlighting its potential to address this high-risk patient population. Read more: https In a patient with type

Tirzepatide is both Mounjaro and Zepbound

Starter Dose Offer: At the time of this post, for a limited time, the starting doses (1.5 mg and 4 mg) are available for as little as $149 per month for eligible self-pay patients

Bariatric surgery has a long track record of safety and effectiveness, and is more cost- effective than GLP-1 medications to treat obesity

the pen is the product format for laboratory handling

Comparing the Cardiovascular Evidence Both semaglutide and dulaglutide have demonstrated significant cardiovascular benefits in large dedicated outcomes trials, which is a major reason why cardiometabolic guidelines increasingly favour GLP-1 receptor agonists for patients with type 2 diabetes and elevated cardiovascular risk